

05-86000-22

Original Effective Date: 02/15/04

Reviewed: 07/25/24

Revised: 12/15/24

## Subject: Tumor/Genetic Markers

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

<a href="#">Position Statement</a>	<a href="#">Billing/Coding</a>	<a href="#">Reimbursement</a>	<a href="#">Program Exceptions</a>	<a href="#">Definitions</a>	<a href="#">Related Guidelines</a>
<a href="#">Other</a>	<a href="#">References</a>	<a href="#">Updates</a>			

### DESCRIPTION:

Serum tumor markers are molecules or substances shed by a tumor into the circulation where they can be detected and quantitated. Noncirculating tumor markers include those that can be detected histochemically or cytogenetically on a tissue sample.

Since serum tumor markers can also be detected in normal or benign lesions, significantly elevated circulating levels may occur with malignancy by one or more of the following mechanisms: overexpression of the antigen by malignant cells; a large tumor burden; or slower clearance of the marker. For example, since the liver clears most tumor markers, liver abnormalities (whether benign, malignant, or inflammatory) may elevate tumor marker concentrations due to impaired clearance. Because most tumor markers are not unique to malignancy, cut-off points must be established for normal versus abnormal marker levels.

The clinical applicability of tumor markers depends on how their measurements are used to influence the management of the patient and whether these management changes will result in an improvement in net health outcome.

**Summary and Analysis of Evidence:** Markers in fine needle aspiration (FNA) of the thyroid: The evidence for patients who receive FNA sample testing with these tests to rule out malignancy and to avoid surgical biopsy or resection, the evidence includes prospective clinical validity studies with the Afirma GSC, a systematic review of prospective and retrospective clinical validity studies, a meta-analysis of real-world post validation data for the Afirma GSC platform with comparison to the validation study, and a chain of evidence to support clinical utility. The meta-analysis of real-world Afirma GSC data indicated significantly higher NPV (as well as specificity and positive predictive value [PPV]) than in the validation study. In other multicenter and single-center studies, there is suggestive evidence that rates of malignancy are low in Afirma GSC or ThyroSeq v3 patients who are classified as benign or negative, with high NPVs in a prospective trial with 31.8 months of post-testing imaging surveillance. The available

evidence suggests that the decisions a physician makes regarding surgery are altered by Afirma GSC or ThyroSeq v3 results. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Evidence for testing to rule in malignancy and to guide surgical planning includes prospective and retrospective studies of clinical validity. Single-center studies have suggested that testing for a panel of genetic variants associated with thyroid cancer may allow for the appropriate selection of patients for surgical management for the initial resection. Prospective studies in additional populations are needed to validate these results. Although the presence of certain variants may predict more aggressive malignancies, the management changes that would occur as a result of identifying higher risk tumors, are not well-established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Evidence for testing to rule out malignancy and avoid surgical biopsy or to rule in malignancy for surgical planning includes multiple retrospective and prospective clinical validation studies for the ThyroSeq test, a systematic review of retrospective and prospective studies, and 2 retrospective clinical validation studies that used a predicate test 17-variant panel (miRInform) test to the current ThyGenX and ThyraMIR. A prospective clinical validation study of ThyroSeq v3 reported an NPV of 97% and PPV of 68%. Similarly, a systematic review including 3 prospective and 3 retrospective clinical validity studies reported an NPV of 92% and PPV of 70%. No prospective studies were identified demonstrating evidence of direct outcome improvements. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Alzheimer disease (AD): Patients who have mild cognitive impairment (MCI) or mild dementia due to AD who are being considered for initial treatment with an approved amyloid beta plaque targeting therapy, the evidence includes randomized controlled trials, multisite longitudinal studies, and an analysis of a mixed cohort. Overall, the diagnostic accuracy of CSF biomarkers versus amyloid PET scans to identify MCI-AD was found to be similar. CSF biomarkers have been used as an alternative to PET amyloid scans to establish eligibility regarding the presence of amyloid beta pathology in randomized controlled trials that showed the efficacy of anti-amyloid therapies, which in turn demonstrates that the CSF biomarkers can identify patients who may benefit from therapy. The FDA-approved labels for lecanemab and donanemab state that the presence of amyloid beta pathology should be confirmed prior to initiating treatment. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome. Patients who are being treated with an amyloid beta plaque targeting therapy and are being evaluated for therapy continuation, the evidence includes multisite longitudinal studies and an analysis of a mixed cohort. The diagnostic accuracy of CSF biomarkers versus amyloid beta PET scans to identify MCI-AD was found to be similar. Further research is required to determine whether the use of CSF biomarkers alone in conjunction with amyloid beta PET scans is useful for determining whether amyloid beta targeting therapy should be continued. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Patients with MCI or dementia who receive urinary biomarker testing for AD, the evidence includes a systematic review. Clinical validity studies have included normal healthy controls and defined optimal test cutoffs without validation; thus, clinical validity is uncertain. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Cutaneous melanoma: Suspicious pigmented lesions considered for biopsy tested with the DermTech Pigmented Lesion Assay to determine which lesions should proceed to biopsy, the evidence includes observational studies. The Pigmented Lesion Assay has 1 clinical validity study with many methodologic and reporting limitations. Also, the test has not been compared with dermoscopy, another tool frequently used to make biopsy decisions. No direct evidence of clinical utility was identified. Given that

the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. The evidence for use of the myPath Melanoma test includes observational studies. In 1 study, it is not clear whether the study population included lesions that were indeterminate following histopathology. The second study focused on indeterminate lesions but had limitations including a retrospective design and less than 5-year follow-up in 31% of cases. No direct evidence of clinical utility was identified. Given that the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Evidence for the use of DecisionDx-Melanoma includes retrospective and prospective observational studies. Zager et al (2018) reported RFS rates of 85% (95% confidence interval [CI], 74% to 97%) for DecisionDx class 2 patients in AJCC stage 1 and 55% (95% CI, 44% to 69%) for DecisionDx class 2 in AJCC stage II disease. The RFS does not appear to be well-characterized as evidenced by the variation in estimates across studies. This indication is to 'rule-in' patients for enhanced surveillance; therefore, specificity and positive predictive value (PPV) are key performance characteristics. In Zager et al (2018) and Greenhaw et al (2018) the specificities were 71% and 87%, respectively, while the PPV were 48% and 24%, respectively. The PPV suggests that the majority of patients identified as high-risk by the DecisionDx test would not develop metastasis and would be unnecessarily subjected to additional surveillance. Greenhaw et al (2018) also reported that in 219 AJCC stage I patients, 201 had DecisionDx class 1 (low-risk) scores and 18 had DecisionDx class 2 (high-risk) scores. The only metastasis in stage I patients occurred in a patient with a DecisionDx class 1 score. Therefore none of their stage 1 patients benefited from DecisionDx testing but 18 (8%) were incorrectly identified as high-risk for metastasis and could have received unnecessary surveillance. Five-year RFS data are not available for the subgroup of patients for whom a 'rule-out' test would be relevant (class IIB through III). There is no evidence that changes to the frequency and methods for surveillance improve outcomes. Given that the evidence is insufficient to demonstrate test performance and there is no evidence that changes in surveillance improve outcomes, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Urinary markers (e.g. Cxbladder™): The evidence for the use of urinary tumor marker tests (e.g. Cxbladder™) for patients who have signs or symptoms of bladder cancer, the evidence includes a number of diagnostic accuracy studies and meta-analyses of these studies. A meta-analysis of diagnostic accuracy studies determined that urinary tumor marker tests have a sensitivity ranging from 47% to 82% and specificity ranging from 53% to 95%. This analysis found that combining urinary tumor markers with cytology improves diagnostic accuracy, but about 10% of cancers would still be missed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Circulating tumor cells (e.g. CellSearch tests): The evidence for testing circulating tumor cells in patients who have cancer to select treatment or monitor treatment response includes observational studies and randomized controlled trial. Published studies reporting clinical outcomes and/or clinical utility are lacking. The uncertainties concerning clinical validity and clinical utility preclude conclusions about whether the use of circulating tumor cells can replace variant analysis of tissue. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Multimarker testing for ovarian cancer: Evidence for the use of multimarker serum testing for patients who have adnexal masses undergoing surgery for possible ovarian cancer includes studies assessing technical performance and diagnostic accuracy. OVA1 and Overa are intended for use in

patients for whom clinical assessment does not clearly indicate cancer. When used in this manner, sensitivity for ovarian malignancy was 92% and specificity was 42% with OVA1; with Overa, sensitivity was 94% and specificity was 65%. ROMA is intended for use with clinical assessment, but no specific method has been defined. One study, which used clinical assessment and ROMA results, showed a sensitivity of 90% and specificity of 67%. However, the National Comprehensive Cancer Network guidelines recommend (category 2A) that all patients with suspected ovarian cancer should be evaluated by an experienced gynecologic oncologist. Given the National Comprehensive Cancer Network recommendation, direct evidence will be required to demonstrate that the use of the testing to inform decisions regarding referral to a gynecologic oncology specialist for surgery has clinical usefulness. Direct evidence of clinical usefulness is provided by studies that have compared health outcomes for patients managed with and without the FDA cleared multimarker serum testing. Because these are intervention studies, the preferred evidence would be from randomized controlled trials. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Human epididymis protein 4 (HE4) biomarker:** The evidence for the use of biomarker HE4 for patients who have ovarian cancer includes 7 nonrandomized prospective and retrospective studies comparing the diagnostic accuracy of HE4 with CA 125 for predicting disease progression and/or recurrence. The superiority of HE4 to CA 125 (alone or in combination), the key question in the evidence review, was not demonstrated in the available literature. In addition, there is no established cutoff in HE4 levels for monitoring disease progression, and cutoffs in studies varied. For patient who adnexal masses the evidence includes diagnostic accuracy studies and meta-analyses. The number of studies evaluating the combined test is relatively low, and publication bias in studies of HE4 has been identified. In addition, studies have not found that HE4 improves diagnostic accuracy beyond that of subjective assessment of transvaginal ultrasound. There is no direct evidence from prospective controlled studies on the impact of HE4 testing on health outcomes, and no clear chain of evidence that changes in management based on HE4 would lead to an improved health outcome. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Pulmonary nodules (e.g. REVEAL, Nodify XL2):** Evidence for the use of plasma based proteomic screening for patients with undiagnosed pulmonary includes prospective cohorts, retrospective studies, and prospective retrospective studies. The Nodify XL2 classifier has undergone substantial evolution, from a 13-protein assay to a 2-protein assay integrated with clinical factors. The classifier has been designed to have high specificity for malignant pulmonary nodules, and the validation study showed a specificity of 97% for patients with a low-to-moderate pretest probability ( $\leq 50\%$ ) of a malignant pulmonary nodule. The primary limitation of this study is that a high number of patients were excluded from the study due to incomplete clinical data or because they were subsequently determined to be outside of the intended use population. Validation in an independent sample in the intended use population is needed. The REVEAL validation study was a retrospective study that demonstrated use as a rule-out test in conjunction with the Veteran's Affairs (VA) Clinical Factors Model when the samples were considered inconclusive or intermediate risk by the VA model. The REVEAL model subsequently correctly identified 65% of intermediate-risk samples as either low or high risk. The negative predictive value and sensitivity were both 94%. Limitations included a small sample size and use in conjunction with just 1 type of testing model. Validation in an independent sample in the intended use population with additional probability models is needed. Indirect evidence suggests that a proteomic classifier with a high negative predictive value has the potential to reduce the number of unnecessary invasive procedures to definitively diagnose benign disease versus malignancy. However, long-term follow-up data would be required to determine the

survival outcomes in patients with a missed diagnosis of lung cancer at earlier, more treatable stages. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Cancers of unknown primary (e.g. Tissue of Origin):** Patients who have cancers of unknown primary who receive gene expression profiling, the evidence includes studies of clinical validity and randomized controlled trials. The clinical validity is the ability of a test to determine the site of origin. Using different reference standards (known tumor type, reference diagnosis, a primary tumor identified during follow-up, immunohistochemical analysis) for the tissue of origin, the tests have reported sensitivities or concordances generally high (e.g., 80% to 90% or more). However, the reference standard is imperfect, and evidence for clinical validity does not support potential benefit. Direct evidence of clinical utility is provided by studies that compare health outcomes for patients managed with and without the test. The benefit would be most convincingly demonstrated through a trial randomizing patients with cancers of unknown primary to receive treatment based on gene expression profiling results or usual care. One published RCT and 1 conference presentation with this design were identified. These trials did not find a survival benefit for patients with cancers of unknown primary who received treatment based on the site of origin as determined by molecular testing. A limitation in interpretation of the published trial results is that there were few treatments that were site specific, so there was minimal difference in the actual treatments given to the 2 groups. In the second RCT, most cancers responded to the control treatments. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Proteomic testing (VeriStrat®):** The evidence for the use of VeriStrat test for patients with advanced non-small cell lung cancer (NSCLC) includes retrospective studies and randomized control trials. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer includes, “Recommend proteomic testing for patients with NSCLC and wild-type EGFR or with unknown EGFR status. A patient with a “poor” classification should not be offered erlotinib in the second-line setting. Proteomic testing can be used to determine whether erlotinib should be used in patients with unknown EGFR status. Erlotinib is superior to best supportive care with significantly improved survival and delayed time in symptom deterioration in patients with non-squamous NSCLC.” The evidence is sufficient for the use of the testing for wild-type tumor (no mutation detected) EGFR OR with unknown EGFR status, failed first-line systemic chemotherapy, and results of the testing to be used to determine whether to proceed with erlotinib therapy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome for all other indications.

**Systemic Lupus (e.g. Avise® tests):** The use of biomarker testing for patients with signs or symptoms of systemic lupus erythematosus (SLE), the evidence includes several diagnostic accuracy studies and a prospective evaluation of clinical utility that compared the impact of the test results on physicians' evaluation of patients with a clinical suspicion for SLE. Observational studies have been primarily retrospective in design, not performed in the intended-use population and lacking concurrent, appropriate comparator. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Squamous cell carcinoma (e.g. DecisionDx®-SCC):** A 2024 article titled, Limitations of the Commercially Available Gene Expression Test in Predicting Cutaneous Squamous Cell Carcinoma Metastasis and Clinical Outcomes (Sax et al) concludes, “Analysis of DecisionDx-SCC indicates potential biases and ambiguities, exacerbated by differences between FDA and CLIA standards. This highlights the need for systematic validation and a unified regulatory approach, stressing the necessity for precise and dependable genetic testing in patient care”. The current data are inadequate to permit scientific conclusions regarding the impact on management decisions and net health outcomes. Guardant360

TissueNext™: A 2023 article titled, Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression (Tran et al) states, “There are limitations to this study. It is a retrospective study at a single, urban academic medical center. Prospective validation in a more heterogeneous patient population or meta-analysis with aggregate datasets may be useful. Paired tests occurred within 24 weeks of each other and without an intervening change in therapy. While this time window was based on prior literature, we acknowledge this is a wide window and ideally this testing would have occurred simultaneously. Only a single platform (Guardant360) was included, and it is unclear if these results are generalizable to all ctDNA testing. Additionally, liquid biopsy tests have historically performed poorly in detecting fusions, which may have limited liquid biopsy sensitivity. Additionally, our analysis centered on variants that are clinically actionable now, at the present time. Both the threshold variant allele frequencies and variants themselves can change over time, thus becoming more (or less) actionable. Therefore, an update to this study will be needed in the future.” No published data was found that assessed the clinical utility and clinical validity of the Guardant360 TissueNext test. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. There is insufficient evidence to support the use of the following tests for all indications: Praxis Extended RAS Panel, PreDx Diabetes Risk Score™; MI Cancer Seek™; Darwin OncoTreat™; Decipher® Bladder TURBT; MSK-Impact; LC-MS/MS Targeted Proteomic assay; NavDx®. Although there may be ongoing clinical studies, the current data are inadequate to permit conclusions regarding the impact on management decisions and net health outcomes.

**POSITION STATEMENT:**

**Note:** Coverage may be governed by state or federal mandates.

<p><b>Evaluation of Biomarkers for Alzheimer Disease</b></p> <p><b>Note:</b> Genetic testing for Alzheimer disease (see MCG 05-82000-28) may be offered along with analysis of cerebral spinal fluid levels of the tau protein and amyloid-b peptide 1-42. This group of tests may be collectively referred to as the Admark™ Profile, offered by Athena Diagnostics.</p>	<p>Cerebrospinal fluid biomarker testing of amyloid beta peptides and tau protein as part of an evaluation for the initiation of amyloid beta targeting therapy in members with mild cognitive impairment or mild dementia due to Alzheimer disease <b>meets the definition of medical necessity.</b></p> <p>Cerebrospinal fluid biomarker testing of neural thread proteins as part of an evaluation for the initiation of amyloid beta targeting therapy in members with mild cognitive impairment or mild dementia due to Alzheimer disease is considered <b>experimental or investigational.</b> The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.</p> <p>Cerebrospinal fluid biomarker testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as an adjunct to clinical diagnosis in members with mild cognitive impairment or members with mild dementia due to Alzheimer disease is considered <b>experimental or investigational.</b> The evidence</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	<p>is insufficient to determine the effects of the technology on health outcomes.</p> <p>Cerebrospinal fluid biomarker testing, including but not limited to amyloid beta peptides, tau protein, or neural thread proteins, as part of an evaluation for the continuation of amyloid beta targeting therapy in members with mild cognitive impairment or mild dementia due to Alzheimer disease is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>Measurement of urinary and blood biomarkers as an adjunct to clinical diagnosis in members with mild cognitive impairment or mild dementia due to Alzheimer disease is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<b>Breast Tumor Markers</b>	<p>CA 15-3 (CA 27.29 or Truquant RIA) <b>meets the definition of medical necessity</b> for the following indications:</p> <ul style="list-style-type: none"><li>• As an aid in the management of Stage II and Stage III breast cancer members. Serial testing for CA 15-3 assay values should be used in conjunction with other clinical methods for monitoring breast cancer</li><li>• As an aid to predict recurrent breast cancer in members with previously treated Stage II or Stage III disease</li><li>• As an aid in monitoring response to therapy in members with Stage IV breast cancer. A partial or complete response to treatment will be confirmed by declining levels. A persistent rise of CA 27-29 levels despite therapy strongly suggests progressive disease.</li></ul> <p>CA 15-3 (CA 27.29 or Truquant RIA) is considered <b>experimental or investigational</b>, as there is insufficient clinical evidence to support the use of CA 15-3 (CA 27.29 or Truquant RIA) as a screening test for breast cancer. There is a lack of clinical data to permit conclusions on efficacy and net health outcomes.</p>

<p><b>Cancer Antigen 125 (CA-125)</b></p>	<p>CA-125 testing <b>meets the definition of medical necessity</b> in individuals with symptoms suggestive of ovarian cancer; symptoms may include:</p> <ul style="list-style-type: none"> <li>• Swelling of the abdomen (ascites)</li> <li>• Gastrointestinal symptoms (e.g., gas, bloating, long-term stomach pain, indigestion)</li> <li>• Bleeding between periods or after menopause</li> <li>• Pelvic pain</li> <li>• Feeling of pressure in the pelvis</li> <li>• Leg pain.</li> </ul> <p>CA-125 testing <b>meets the definition of medical necessity</b> in individuals with other gynecologic malignancies, such as endometrial cancer, in whom baseline levels of CA-125 have been shown to be elevated.</p> <p>CA-125 testing in asymptomatic individuals is considered <b>experimental or investigational</b>. There is insufficient clinical evidence to support the use of CA-125 testing as a screening technique for ovarian cancer.</p>
<p><b>Cardiovascular Disease Risk Panels</b></p> <p>(Cardiovascular risk panels may include: Applied Genetics Cardiac Panel; Boston Heart Advanced Risk Markers Panel; Cleveland HeartLab CVD Inflammatory Profile; Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel; Genova Diagnostics CV Health Plus Genomics™ Panel; Health Diagnostics Cardiac Risk Panel; Metametrix Cardiovascular Health Profile; MI-HEART Ceramides; Spectracell LPP™.)</p>	<p>Cardiovascular disease risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels*), are considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>*A simple lipid panel is generally composed of the following lipid measures: Total cholesterol; LDL cholesterol; HDL cholesterol; Triglycerides. Certain calculated ratios, such as the total/HDL cholesterol may also be reported as part of a simple lipid panel. Other types of lipid testing, i.e., apolipoproteins, lipid particle number or particle size, lipoprotein (a), etc., are not considered to be components of a simple lipid profile.</p>



<p><b>Gene Expression Profiling for Colorectal Cancer</b></p>	<p>Gene expression profiling (e.g., ColonSentry<sup>®</sup>, BeScreened<sup>™</sup>-CRC) is considered <b>experimental or investigational</b> for colorectal cancer screening. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.</p>
<p><b>Tumor-Informed Circulating Tumor DNA</b></p>	<p>Tumor-informed circulating tumor DNA testing (e.g., Signatera<sup>™</sup>) is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Cutaneous Melanoma</b></p> <p>(DecisionDx DiffDx- Melanoma)</p>	<p>Gene expression testing, including but not limited to the Pigmented Lesion Assay (PLA), in the evaluation of members with suspicious pigmented lesions is considered <b>experimental or investigational</b>.</p> <p>Gene expression testing, including but not limited to the myPath Melanoma test, in the evaluation of members with melanocytic lesions with indeterminate histopathologic features is considered <b>experimental or investigational</b>.</p> <p>Gene expression testing, including but not limited to DecisionDx-Melanoma, in the evaluation of members with cutaneous melanoma is considered <b>experimental or investigational</b> for all indications.</p> <p>The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification</b></p> <p>(MyPRS<sup>™</sup>/MyPRS Plus<sup>™</sup>)</p>	<p>Microarray-based gene expression profile testing for multiple myeloma is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>FDA Cleared or Approved Companion Diagnostic Devices</b></p>	<p>Biomarker identification <b>meets the definition of medical necessity</b> when confirmation is required per the “Indications and Usage” of the FDA-approved prescribing label prior to initiating therapy.</p> <p>List of Cleared or Approved Companion Diagnostic Devices can be found at: <a href="https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools">https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools</a></p>

**Molecular Markers in Fine Needle Aspirates of the Thyroid**

For members who have thyroid nodules without strong clinical or radiologic findings suggestive of malignancy in whom surgical decision making would be affected by test results, the use of either of the following types of molecular marker testing or gene variant analysis in fine needle aspirates of thyroid nodules with indeterminate cytologic findings (i.e., Bethesda diagnostic category III [atypia/follicular lesion of undetermined significance] or Bethesda diagnostic category IV [follicular neoplasm/suspicion for a follicular neoplasm]) **meets the definition of medical necessity:**

- Afirma<sup>®</sup> Genomic Sequencing Classifier; or
- ThyroSeq<sup>®</sup>.

The use of any of the following types of molecular marker testing or gene variant analysis in fine needle aspirates of thyroid nodules with indeterminate findings (Bethesda diagnostic category III [atypia/follicular lesion of undetermined significance] or Bethesda diagnostic category IV [follicular neoplasm/suspicion for a follicular neoplasm]) or suspicious findings (Bethesda diagnostic category V [suspicious for malignancy]) to rule in malignancy to guide surgical planning for initial resection rather than a 2-stage surgical biopsy followed by definitive surgery **meets the definition of medical necessity:**

- ThyroSeq;
- ThyraMIR<sup>®</sup> microRNA/ThyGenX<sup>®</sup>;
- Afirma BRAF after Afirma Genomic Sequencing Classifier; or
- Afirma MTC after Afirma Genomic Sequencing Classifier.

Gene expression classifiers, genetic variant analysis, and molecular marker testing in fine needle aspirates of the thyroid not meeting criteria outlined above, including but not limited to use of RosettaGX Reveal and single-gene TERT testing, are considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.

<p><b>Holo-Transcobalamin</b></p>	<p>Measurement of holo-transcobalamin, including but not limited to its use in the diagnosis and management of vitamin B12 deficiency, is considered <b>experimental or investigational</b>. There is insufficient clinical evidence to support the use of the measurement of holo-transcobalamin to identify early states of vitamin B12 deficiency. There are inadequate data to establish holo-TC testing as an alternative to either serum cobalamin or levels of MMA or homocysteine.</p>
<p><b>Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes</b></p>	<p>Measurement of long chain omega-3 fatty acids in red blood cell membranes is considered <b>experimental or investigational</b>, as there is insufficient clinical evidence to support the use of the measurement of long chain omega-3 fatty acids as a cardiac risk factor. There is a lack of scientific evidence in the published literature regarding how measurements of red blood cell omega-3 fatty acid would affect management of individuals at risk for or members with coronary artery disease (CAD).</p>
<p><b>Management of Pulmonary Nodules</b></p> <p>(Nodify CDT<sup>®</sup>, REVEAL Lung Nodule Characterization)</p>	<p>Plasma-based proteomic screening, including but not limited to BDX-XL2 (Nodify XL2<sup>®</sup>), in members with undiagnosed pulmonary nodules detected by computed tomography is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>Gene expression profiling on bronchial brushings, including but not limited to Percepta<sup>®</sup> Genomic Sequencing Classifier, in members with indeterminate bronchoscopy results from undiagnosed pulmonary nodules is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Measurement of Serum Antibodies to Selected Biologic Agents (e.g. infliximab, adalimumab, vedolizumab, or ustekinumab)</b></p> <p>(LabCorp<sup>®</sup> Adalimumab Concentration &amp; Anti-Adolimumab Antibody; Prometheus<sup>®</sup> Anser<sup>™</sup> IFX; Prometheus<sup>®</sup> Anser<sup>™</sup> ADA;</p>	<p>Measurement of antidrug antibodies in a member receiving treatment with a biologic agent, either alone or as a combination test, which includes the measurement of serum TNF blocking agent levels, is considered <b>experimental or investigational</b>. There is insufficient evidence in medical literature regarding the clinical utility and impact on clinical outcomes to permit conclusions on net health outcomes.</p>

<p>Prometheus<sup>®</sup> Anser UST; Prometheus<sup>®</sup> Anser<sup>™</sup> VDZ )</p>	
<p><b>Gene Expression-Based Assays for Cancers of Unknown Primary</b></p> <p>(CancerTYPE ID<sup>®</sup>, MiRview<sup>®</sup> tests, Tissue of Origin<sup>®</sup>, ProOnc TumorSource DX<sup>™</sup>, RosettaGX Cancer Origin<sup>™</sup> (formerly miRview<sup>®</sup> met<sup>2</sup>).</p>	<p>Gene expression profiling is considered <b>experimental or investigational</b> to evaluate the site of origin of a tumor of unknown primary, or to distinguish a primary from a metastatic tumor. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multianalyte Assays for Chronic Liver Disease</b></p>	<p>A single FibroSURE<sup>®</sup> multianalyte assay <b>meets the definition of medical necessity</b> for the evaluation of members with chronic liver disease.</p> <p>FibroSURE<sup>®</sup> multianalyte assays are considered <b>experimental or investigational</b> for monitoring members with chronic liver disease. The evidence is insufficient to determine the effects of the technology on health outcomes.</p> <p>The use of other multianalyte assays with algorithmic analyses (e.g. FIBROSpect<sup>®</sup> II) is considered <b>experimental or investigational</b> for the evaluation or monitoring of members with chronic liver disease. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multibiomarker Disease Activity Score for Rheumatoid Arthritis</b></p> <p>(Prism<sup>™</sup> RA)</p>	<p>The use of a multibiomarker disease activity score for rheumatoid arthritis (e.g., Vectra<sup>®</sup> score) is considered <b>experimental or investigational</b> in all situations. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multicancer Early Detection Testing</b></p>	<p>The use of multicancer early detection (MCED) tests (e.g. Galleri<sup>®</sup>) is considered <b>experimental or investigational</b> for cancer screening. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Multimarker Serum Testing Related to Ovarian Cancer</b></p>	<p>All uses of the Ova1<sup>®</sup>, Ova1Plus<sup>®</sup>, Overa<sup>™</sup>, OvaWatch<sup>sm</sup>, and ROMA<sup>™</sup> tests are considered <b>experimental or investigational</b>, including but not limited to:</p> <ul style="list-style-type: none"> <li>• preoperative evaluation of adnexal masses to triage for malignancy</li> </ul>

	<ul style="list-style-type: none"> <li>• screening for ovarian cancer</li> <li>• selecting members for surgery for an adnexal mass</li> <li>• evaluation of members with clinical or radiologic evidence of malignancy</li> <li>• evaluation of members with nonspecific signs or symptoms suggesting possible malignancy, or</li> <li>• postoperative testing and monitoring to assess surgical outcome and/or to detect recurrent malignant disease following treatment.</li> </ul> <p>The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Pharmacogenomic and Metabolite Markers for Members Treated with Thiopurines</b></p>	<p>One-time genotypic or phenotypic analysis of thiopurine methyltransferase (TPMT) and nudix hydrolase (NUDT15) <b>meets the definition of medical necessity</b> in members beginning therapy with azathioprine (AZA), mercaptopurine (6-MP), thioguanine, or in members on thiopurine therapy with abnormal complete blood count (CBC) results that do not respond to dose reduction.</p> <p>Genotypic and/or phenotypic analysis of TPMT and NUDT15 is considered <b>experimental or investigational</b> for all other indications. The evidence is insufficient to determine the effects of technology on net health outcomes.</p> <p>Analysis of the metabolite markers of azathioprine (AZA) and mercaptopurine (6-MP), including 6-methyl-mercaptopurine ribonucleotides (6-MMRP) and 6-thioguanine nucleotides (6-TGN), is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of technology on net health outcomes.</p>
<p><b>Proteogenomic Testing for Members With Cancer</b></p>	<p>Proteogenomic testing of members with cancer (including but not limited to GPS Cancer™ test) is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effect of the technology on health outcomes.</p>
<p><b>Proteomic Testing for Advanced Non-Small Cell Lung Cancer (NSCLC)</b></p>	<p>Proteomic testing (VeriStrat®) <b>meets the definition of medical necessity</b> for members with advanced non-small cell lung cancer (NSCLC) meeting <b>ALL</b> of the following criteria:</p>

	<ul style="list-style-type: none"> <li>• tumor is wild-type (no mutation detected) EGFR <b>OR</b> with unknown EGFR status;</li> <li>• failed first-line systemic chemotherapy; <b>AND</b></li> <li>• test results will determine whether to proceed with erlotinib (Tarceva®) therapy.</li> </ul> <p>Proteomic testing (VeriStrat) is considered <b>experimental or investigational</b> for all other indications. There is insufficient evidence to permit conclusions on clinical utility or net health outcomes.</p>
<p><b>Serum Biomarker Human Epididymis Protein 4</b></p> <p>(Architect HE4 assay, Elecsys HE4, HE4 EIA Kit, HE4 immunoassay, Lumipulse G HE4 Immunoreaction)</p>	<p>Measurement of human epididymis protein 4 (HE4) is considered <b>experimental or investigational</b> for all indications. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases</b></p> <p>(Avisé® CTD, Avisé® Lupus, Avisé® Monitor, Avisé® MTX, Avisé®, PG, Avisé® Prognostic, Avisé® SLE, Avisé® SLE+)</p>	<p>Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>
<p><b>Serum Biomarker Tests for Multiple Sclerosis</b></p>	<p>Serum biomarker tests (e.g. gMS® Dx, gMS® Pro EDSS) for multiple sclerosis are considered <b>experimental or investigational</b> for all indications. There is insufficient evidence from prospective studies demonstrating improved health outcomes in individuals who may have multiple sclerosis and who are treated according to test results.</p>
<p><b>Uveal Melanoma</b></p>	<p>Gene expression profiling for uveal melanoma with DecisionDx-UM <b>meets the definition of medical necessity</b> for members with primary, localized uveal melanoma.</p> <p>Gene expression profiling for uveal melanoma that do not meet the above criteria is considered <b>experimental or investigational</b>. The evidence is insufficient to determine the effects of the technology on health outcomes.</p>

The following tumor markers are considered **experimental or investigational** for all indications, as there is insufficient evidence in the peer reviewed medical literature to support the use of these markers for screening, diagnosing, staging, surveillance or monitoring response to treatment:

**Table 1**

<u>a2-PAG</u>	pregnancy-associated alpha-2-glycoprotein
<u>BCM</u>	breast cancer mucin
CA50	cancer antigen 50
CA72-4	cancer antigen 72-4
CA195	cancer antigen 195
CA242	cancer antigen 242
CA549	carbohydrate antigen/cancer antigen 594
CA-SCC	squamous cell carcinoma antigen
<u>CAM17-1</u>	monocolonal antimucin antibody 17-1
CAM26	monocolonal antimucin antibody 26
CAM29	monocolonal antimucin antibody 29
<u>CAR-3</u>	antigenic determinant recognized by monoclonal antibody AR-3
<u>DU-PAN-2</u>	sialylated carbohydrate antigen DU-PAN-2
<u>MCA</u>	mucin-like carcinoma-associated antigen
<u>NSE</u>	neuron-specific enolase
PLAP	placental alkaline phosphatase
<u>PNA/ELLA</u>	peanut lectin bonding assay
<u>SLEX</u>	sialylated Lewis X-I antigen
<u>SLX</u>	sialylated SSEA-1 antigen
<u>SPAN-1</u>	sialylated carbohydrate antigen SPAN-1
<u>ST-439</u>	sialylated carbohydrate antigen ST-439
<u>TAG12</u>	tumor-associated glycoprotein 12
<u>TAG72</u>	tumor-associated glycoprotein 72
<u>TAG72.3</u>	tumor-associated glycoprotein 72.3
<u>TATI</u>	tumor-associated trypsin inhibitor
<u>TNF-a</u>	tumor necrosis factor alpha
<u>TPA</u>	tissue polypeptic antigen

Home testing (including self-testing home kits) is considered **experimental or investigational** for all indications. The clinical validity of the tests have not been established and the evidence is insufficient to determine the effects of the technology on health outcomes.

**The following tests are considered experimental or investigational**, as there is insufficient evidence to support the use of these tests for all indications. Although there are ongoing clinical studies the current data are inadequate to permit scientific conclusions regarding the impact on management decisions and net health outcomes.

- Academic Profile
- Advise MCV

- CellSearch® Circulating Multiple Myeloma Cell
- CellSearch® HER2 Circulating Tumor Cell
- Cxbladder™ /Cxbladder Detect
- Darwin OncoTreat™ (formerly OncoTreat)
- Decipher® Bladder TURBT
- DecisionDx® -SCC
- DetermaRx™ mRNA
- FiT IQ™
- GeneSearch™ BLNHeproDx-TM
- Guardant360 TissueNext™
- HERmark®
- InflammDry®
- KidneyIntelX™
- LC-MS/MS Targeted
- MI Cancer Seek™
- MSK-Impact™
- NavDx®
- NETest
- OncoExTra™ (formerly Oncomap ExTra and GEM ExTra)
- Oncomap™ (formerly Oncotype MAP)
- Ova Check™
- OvaSure™
- PathwayFit®
- PGDx elio™ Tissue Complete
- PharmaRisk™
- Post-Op Px™ (previously known as ProstatePX)
- Praxis Extended RAS Panel
- PreDx Diabetes Risk Score™
- Prostate Px+
- ResponseDX: Lung™
- ResponseDX: Colon™
- Thyroid Cancer Mutation Panel.

## BILLING/CODING INFORMATION:

**Note: Code list may not be all-inclusive.**

### CPT Coding:

80145	Adalimumab ( <b>Investigational</b> )
80230	Infliximab ( <b>Investigational</b> )
80280	Vedolilzumab ( <b>Investigational</b> )
81191	NTRK1 (neurotrophic receptor tyrosine kinase 1) (e.g., solid tumors) translocation analysis
81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (e.g., solid tumors) translocation analysis



81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (e.g., solid tumors) translocation analysis
81194	NTRK (neurotrophic-tropomyosin receptor tyrosine kinase 1, 2, and 3) (e.g., solid tumors) translocation analysis
81335	TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3)
81345	TERT (telomerase reverse transcriptase) (e.g., thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (e.g., promoter region) <b>(Investigational)</b>
81490	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score <b>(Investigational)</b>
81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score <b>(Investigational)</b>
81503	Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin and pre-albumin), utilizing serum, algorithm reported as a risk score <b>(Investigational)</b>
81504	Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores <b>(Investigational)</b>
81506	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score <b>(Investigational)</b>
81517	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years <b>(Investigational)</b>
81529	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis <b>(Investigational)</b>
81538	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival
81540	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype <b>(Investigational)</b>
81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (e.g., benign or suspicious)
81552	Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis

81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (e.g., positive or negative for high probability of usual interstitial pneumonia [UIP]) <b>(Investigational)</b>
81596	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
84433	Thiopurine S-methyltransferase (TPMT)
86152	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood) <b>(Investigational)</b>
86153	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood); physician interpretation and report, when required <b>(Investigational)</b>
86300	Immunoassay for tumor antigen, Quantitative; CA 15-3 (27.29)
86304	Immunoassay for tumor antigen, CA-125
86305	Human epididymis protein 4 (HE4) <b>(Investigational)</b>
86316**	Immunoassay for tumor antigen; other antigen, quantitative (e.g., CA 50, 72-4, 549), each <b>(Investigational)</b>
0002M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ASH)
0003M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH)
0006M	Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier <b>(Investigational)</b>
0007M	Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index <b>(Investigational)</b>
0012M	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and XCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma <b>(Investigational)</b>
0013M	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma <b>(Investigational)</b>
0016M	Oncology (bladder), mRNA, microarray gene expression profiling of 219 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like) <b>(Investigational)</b>

0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified <b>(Investigational)</b>
0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score <b>(Investigational)</b>
0018U	Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy
0019U	Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents <b>(Investigational)</b>
0026U	Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result (“Positive, high probability of malignancy” or “Negative, low probability of malignancy”)
0034U	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(e.g., thiopurine metabolism) gene analysis, common variants (i.e., TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)
0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s) <b>(Investigational)</b>
0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score <b>(Investigational)</b>
0080U	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy <b>(Investigational)</b>
0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) <b>(Investigational)</b>
0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (i.e., benign, indeterminate, malignant) <b>(Investigational)</b>
0091U	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result <b>(Investigational)</b>
0092U	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy <b>(Investigational)</b>

0105U	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD) <b>(Investigational)</b>
0111U	Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue <b>(Investigational)</b>
0119U	Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events <b>(Investigational)</b>
0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas <b>(Investigational)</b>
0166U	Liver disease, 10 biochemical assays ( $\alpha$ 2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation <b>(Investigational)</b>
0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism) gene analysis, common variants
0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents <b>(Investigational)</b>
0179U	Oncology (non-small cell lung cancer), cell free DNA, targeted sequence analysis of 23 genes [single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations], with report of significant mutation(s) <b>(Investigational)</b>
0206U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKC $\epsilon$ ) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease <b>(Investigational)</b>
0207U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKC $\epsilon$ ) concentration in response to amylospheroid treatment by ELISA, quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) <b>(Investigational)</b>
0211U	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association <b>(Investigational)</b>

0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue <b>(Investigational)</b>
0245U	Oncology (thyroid), mutation analysis of 10 genes and 37 RNA fusions and expression of 4 mRNA markers using next generation sequencing, fine needle aspirate, report includes associated risk of malignancy expressed as a percentage
0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden <b>(Investigational)</b>
0287U	Oncology (thyroid), DNA and mRNA, next generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high) <b>(Investigational)</b>
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score <b>(Investigational)</b>
0312U	Autoimmune diseases (e.g., systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment <b>(Investigational)</b>
0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (i.e., benign, intermediate, malignant) <b>(Investigational)</b>
0315U	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (i.e., Class 1, Class 2A, Class 2B) <b>(Investigational)</b>
0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations <b>(Investigational)</b>
0334U	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden <b>(Investigational)</b>

0337U	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood <b>(Investigational)</b>
0338U	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood <b>(Investigational)</b>
0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate <b>(Investigational)</b>
0356U	Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence <b>(Investigational)</b>
0358U	Neurology (mild cognitive impairment), analysis of B-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative
0360U	Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy <b>(Investigational)</b>
0363U	Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma <b>(Investigational)</b>
0375U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [i.e., transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score <b>(Investigational)</b>
0412U	Beta amyloid, A $\beta$ 42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoformspecific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology <b>(Investigational)</b>
0420U	Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma <b>(Investigational)</b>
0445U	$\beta$ -amyloid (Abeta42) and phosphor tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
0459U	B-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology

0490U	Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma associated antigen, CD34 and CD45 protein biomarkers, peripheral blood ( <b>Investigational</b> )
0491U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood ( <b>Investigational</b> )
0492U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood ( <b>Investigational</b> )

\*\*May be covered when used to report the Chromogranin A (CgA) test for neuroendocrine tumors (i.e. carcinoid tumors).

### ICD-10 Diagnosis Codes That Support Medical Necessity for 81335, 0034U, 0169U

K50.00-K50.019	Crohn's disease of small intestine
K51.00-K51.319	Ulcerative colitis

### ICD-10 Diagnosis Codes That Support Medical Necessity for 81538

C34.00 – C34.92	Malignant neoplasm of bronchus and lung
-----------------	-----------------------------------------

### ICD-10 Diagnosis Codes That Support Medical Necessity for 81546

C73	Malignant neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland

### ICD-10 Diagnosis Codes That Support Medical Necessity for 81552

C69.00-C69.92	Malignant neoplasm of eye and adnexa
---------------	--------------------------------------

### ICD-10 Diagnosis Codes That Support Medical Necessity for 86300

C50.011 – C50.929	Malignant neoplasm of breast
C79.2	Secondary malignant neoplasm of skin
C79.81	Secondary malignant neoplasm of breast
G89.3	Neoplasm related pain (acute) (chronic)
R97.8	Other abnormal tumor markers
Z85.3	Personal history of malignant neoplasm of breast

### ICD-10 Diagnosis Codes That Support Medical Necessity for 86304

C45.1	Mesothelioma of peritoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C53.0	Malignant neoplasm of endocervix

C53.1	Malignant neoplasm of exocervix
C54.1 – C54.9	Malignant neoplasm of corpus uteri
C56.1 – C56.9	Malignant neoplasm of ovary
C57.00 – C57.9	Malignant neoplasm of other and unspecified female genital organs
C79.60	Secondary malignant neoplasm of ovary, unspecified side
C79.61	Secondary malignant neoplasm of right ovary
C79.62	Secondary malignant neoplasm of left ovary
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
D39.0, D39.10 – D39.12 D39.7 – D39.9	Neoplasm of uncertain behavior of female genital organs
G89.3	Neoplasm related pain (acute) (chronic)
R19.00	Intra-abdominal and pelvic swelling, mass and lump, unspecified site
R19.01	Right upper quadrant abdominal swelling, mass and lump
R19.02	Left upper quadrant abdominal swelling, mass and lump
R19.03	Right lower quadrant abdominal swelling, mass and lump
R19.04	Left lower quadrant abdominal swelling, mass and lump
R19.05	Periumbilical swelling, mass or lump
R19.06	Epigastric swelling, mass or lump
R19.07	Generalized intra-abdominal and pelvic swelling, mass and lump
R19.09	Other intra-abdominal and pelvic swelling, mass and lump
R97.1	Elevated cancer antigen 125 [CA 125]
R97.8	Other abnormal tumor markers
Z85.40	Personal history of malignant neoplasm of unspecified female genital organ
Z85.41	Personal history of malignant neoplasm of cervix uteri
Z85.42	Personal history of malignant neoplasm of other parts of uterus
Z85.43	Personal history of malignant neoplasm of ovary
Z85.44	Personal history of malignant neoplasm of other female genital organs

### ICD-10 Diagnosis Codes That Support Medical Necessity for 0018U

C73	Malignant neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland

### ICD-10 Diagnosis Codes That Support Medical Necessity for 0026U

C73	Malignant neoplasm of thyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland

### REIMBURSEMENT INFORMATION:

The following information is required documentation to support medical necessity: physician history and physical, physician progress notes, laboratory studies, treatment plan, and physician operative report (if applicable).



## LOINC Codes

Documentation Table	LOINC Codes	LOINC Time Frame Modifier Code	LOINC Time Frame Modifier Codes Narrative
Physician history and physical	28626-0	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Attending physician progress note	18741-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Plan of treatment	18776-5	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Laboratory studies	26436-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Physician operative report	28573-4	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim

## PROGRAM EXCEPTIONS:

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

### Medicare Advantage Products:

The following National Coverage Determinations (NCD) were reviewed on the last guideline reviewed date and located at [cms.gov](https://www.cms.gov): Tumor Antigen by Immunoassay-CA 125 (190.28); Tumor Antigen by Immunoassay-CA 15-3/CA 27.29 (190.29); Tumor Antigen by Immunoassay-CA19-9 (190.30); Next Generation Sequencing (NGS) (90.2).

The following Local Coverage Determinations (LCDs) are located at [fcso.com](https://www.fcso.com): Molecular Pathology Procedures (L34519); Pharmacogenomics Testing (L39073).

The following Billing and Coding Articles are located at [fcso.com](https://www.fcso.com): Molecular Pathology and Genetic Testing (A58918); Molecular Pathology Procedures (A57451).

The following are located at [cms.gov](https://www.cms.gov): Molecular Diagnostic Services (MoIDX) coverage determinations.

## DEFINITIONS:

**A2-PAG:** pregnancy-associated alpha-2 glycoprotein (a chemical made by some cancers, consisting of a combination of protein and sugars).

**BCM:** breast cancer mucin; a marker made by some breast cancers.

**CAM17-1, CAM26, CAM29:** also known as monoclonal anti-mucin antibody markers, are markers noted in certain cancers.

**CAR-3:** a marker that reacts with a special test using a specific protein testing substance called “monoclonal antibody AR-3”.

**Carbohydrate cancer antigens:** CA 19-9, CA-125, CA 15-3/CA27-23, CA 242, CA 50, CA 72-4, CA 195, CA 549, M26, M29: these and other markers are a way to test for special markers on tumors, that are made of carbohydrates (a chemical that resembles a type of sugar).

**CgA:** a major protein of the granin family that has been described as a potential marker for neuroendocrine tumors.

**CellSearch®:** a serum-based test that measures circulating tumor cells.

**DU-PAN-2:** a chemical (sialylated carbohydrate antigen) that may be found with some cancers.

**FibroSpect II:** serum marker panels for the diagnosis or clinical management of liver disease.

**FibroSure:** serum marker panels for the diagnosis or clinical management of liver disease.

**GeneSearch BLN:** an assay for the detection of greater than 0.2mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients.

**HE4:** an enzyme immunoassay for the quantitative determination of Human Epididymis Protein 4 (HE4) antigen in ovarian cancer.

**LPA:** lysophosphatidic acid; a chemical that has been suggested as a possible test for ovarian cancer, body levels may be high in other cancers as well.

**MCA:** a chemical (Mucin-like Carcinoma-associated Antigen) that may be found in breast cancers.

**MSA:** a chemical (Mammary Serum Antigen) that may be found in breast cancers.

**NSE:** Neuron-Specific Enolase, a chemical made in the presence of some cancers.

**Ova Check™:** a serum-based test for the early detection of epithelial ovarian cancer.

**OvaSure™:** ovarian cancer-screening test that may be able to assess the presence of early stage ovarian cancer in high-risk woman.

**Pathwork Tissue of Origin:** a diagnostic test that may aid in the diagnosis of tumors with uncertain origins.

**P-LAP:** placental alkaline phosphatase, a chemical made in the presence of some cancers.

**PNA/ELLA:** peanut lectin bonding assay, a test for a certain tumor marker.

**Proteogenomic Testing:** involves the integration of proteomic, transcriptomic, and genomic information.

**Proteomic Testing:** the measurement of protein products *alone*, without integration of genomic and transcriptomic information.

**SLEX, SLX:** sialylated Lewis X-I antigen and sialylated SSEA-1 antigen.

**SPAN-1:** a sialylated carbohydrate antigen.

**ST-439:** a sialylated carbohydrate antigen.

**TAG12, TAG 72, TAG 72.3:** tumor associated glycoproteins; chemicals made by some cancers, consisting of a combination of protein and sugars.

**TATI:** tumor-associated trypsin inhibitor, a chemical made by the body, in the presence of some cancers.

**TNF-a:** tumor necrosis factor alpha, a chemical made by the immune system in the presence of some cancers.

**TPA:** tissue polypeptide antigen is a marker that may be present on some cancers.

## RELATED GUIDELINES:

[Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer, 05-86000-26](#)

[Genetic Testing, 05-82000-28](#)

[Molecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions, 05-86000-27](#)

[Somatic Biomarker Testing \(Including Liquid Biopsy\) for Targeted Treatment in Metastatic Colorectal Cancer \(KRAS, NRAS, BRAF, NTRK, and HER2\), 05-86000-28](#)

## OTHER:

None applicable.

## REFERENCES:

1. Akerley WL, et al, The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer, *Curr Med Res Opin.* 2013 May;29(5):517-25.
2. Alexander EK, Schorr M, Kloppner J, et al. Multicenter clinical experience with the Afirma gene expression classifier. *J Clin Endocrinol Metab.* Jan 2014;99(1):119-125.
3. American Academy of Dermatology. Clinical Guidelines; accessed at aad.org.
4. American Academy of Ophthalmology, Preferred Practice Pattern: Dry Eye Syndrome, 2013. Accessed at aao.org 09/22/16.

5. American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). Recommendations for Testing, Managing, and Treating Hepatitis C. 2016; accessed at [hcvguidelines.org](http://hcvguidelines.org).
6. American College of Obstetricians and Gynecologists, Committee Opinion Number 477- The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer, March 2011.
7. American Society of Clinical Oncology (ASCO). Clinical Guidelines; accessed at [asco.org](http://asco.org).
8. American Society of Clinical Oncology (ASCO) Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small Cell Lung Cancer Considering First-Line EGFR Tyrosine-Kinase Inhibitor (TKI) Therapy, 2011. Accessed at [asco.org](http://asco.org) 04/02/13.
9. Arnot SP, Han G, et al. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. *Am J Surg*. 2021 Jun;221(6):1195-1199. PMID:33773750.
10. Bailey CN, Martin BJ, et al. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. *JCO Precis Oncol*. 2023 Jun;7:e2300044.
11. Bastien AJ, Ng J, et al. Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma. *Oral Oncol*. 2024 Sep;156:106894. PMID: 38909394.
12. Berger BM, Hanna GJ, et al. Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. *Clin Cancer Res*. 2022 Oct 3;28(19):4292-4301. PMID: 35576437.
13. Berman B, Ceiley R, et al. Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. *SKIN*. 2019; 3(5):291-298.
14. Bhamhani C, Sanford E, et al. Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma. *Oral Oncol*. 2023 Aug;143:106436. PMID: 7269557.
15. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.07 Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance, 01/24.
16. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.14, Evaluation of Biomarkers for Alzheimer Disease, 11/24.
17. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.19 Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines, 12/23.
18. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.41 Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease, 12/23.
19. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.54 Gene Expression–Based Assays for Cancers of Unknown Primary, 04/24.
20. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.62, Multimarker Serum Testing Related to Ovarian Cancer, 01/24.
21. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.66 Serum Biomarker Human Epididymis Protein 4, 01/24.

22. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.78 Molecular Markers in Fine Needle Aspirates of the Thyroid, 09/24.
23. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.84 Measurement of Serum Antibodies to Selected Biologic Agents, 12/23.
24. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.97 Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification, 11/24.
25. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.100, Cardiovascular Risk Panels, 01/24.
26. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>. 2.04.115 Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies, 11/24.
27. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.119 Multibiomarker Disease Activity Blood Test for Rheumatoid Arthritis, 07/24.
28. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.120, Gene Expression Profiling for Uveal Melanoma, 03/24.
29. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.121, Miscellaneous Genetic and Molecular Diagnostic Tests, 08/24.
30. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.123, Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases, 07/24.
31. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.125 Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer, 12/23.
32. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.140, Proteogenomic Testing for Patients With Cancer, 07/24.
33. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>. 2.04.141 Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy), 09/24.
34. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup> 2.04.142, Molecular Testing in the Management of Pulmonary Nodules, 06/24.
35. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.146 Gene Expression Profiling for Cutaneous Melanoma, 06/24.
36. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>, 2.04.150 Serologic Genetic and Molecular Screening for Colorectal Cancer, 08/24.
37. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>; 2.04.153 Tumor-Informed Circulating Tumor DNA Testing for Cancer Management, 10/24.
38. Blue Cross Blue Shield Association Evidence Positioning System<sup>®</sup>; 2.04.158 Multicancer Early Detection Testing, 07/24.
39. Boac BM, Xiong Y, et al. Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. *Am J Obstet Gynecol*. 2018 Apr;218(4): 436.e1-436.e7.
40. Borman S, Wilkinson J, et al. Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients. *Diagn Pathol*. 2022; 17: 32. Published online 2022 Feb 25.

41. Brodsky BS, Owens GM, et al, Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers, AHDB October 2017 Vol 10, No 7.
42. Brouha B, Ferris LK, et al. Real-World Utility of a Non-Invasive Gene Expression Test to Rule Out Primary Cutaneous Melanoma: A Large US Registry Study. *J Drugs Dermatol*. 2020 Mar 1;19(3):257-262.
43. Buzaid AC, Gershenwals JE. Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma. In: UpToDate, Atkins MB, Shah S (Eds), UpToDate, Waltham, MA; accessed May 2023 at uptodate.com.
44. Carbone et al, Clinical Validity: BR21 – Prognostic Effect of VeriStrat, *Journal of Thoracic Oncology*, 2012.
45. Castle Biosciences, Inc. DecisionDx<sup>®</sup>-Melanoma Clinical Dossier, 2023.
46. Castle Biosciences, Inc. myPath<sup>®</sup> Melanoma Clinical Dossier, 2023.
47. Castle Biosciences, Inc. myPath<sup>®</sup> Melanoma Technology Updates, 2022.
48. Centers for Medicare & Medicaid Services (CMS). Molecular Diagnostic Services (MolDX) Coverage Determinations, accessed at cms.gov.
49. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) Next Generation Sequencing (NGS) (90.2); accessed at cms.gov.
50. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Tumor Antigen by Immunoassay- CA 125 (190.28), accessed at cms.gov.
51. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Tumor Antigen by Immunoassay- CA 15-3/CA 27.29 (190.29), accessed at cms.gov.
52. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Tumor Antigen by Immunoassay – CA19-9 (190.30), accessed at cms.gov.
53. Chakravarty D, Johnson A, et al. Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. *J Clin Oncol*. 2022 Apr 10;40(11):1231-1258.
54. Chan, D.W., Beveridge, R.A., Muss, H., et al., Use of Truquant BR Radioimmunoassay for Early Detection of Breast Cancer Recurrence in Patients with Stage II and Stage III Disease. *Journal of Clinical Oncology*. 1997; Vol. 15(6): 2322-2328.
55. Chan L, Nadkarni GN, et al. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. *Diabetologia*. 2021 Jul;64(7):1504-1515.
56. Chu QS. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. *Ther Adv Med Oncol*. 2020 Jan 23; 12:1758835919895756.
57. Cibas ES, Ali SZ, The 2017 Bethesda System for Reporting Thyroid Cytopathology. *Thyroid*. 2017 Nov;27(11):1341-1346.
58. Cibas ES, Baloch ZW, et al, A prospective assessment defining the limitations of thyroid nodule pathologic evaluation; *Ann Intern Med*. 2013 Sep 3;159(5):325-32.

59. Clark TA, Chung JH, et al. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. *J Mol Diagn.* 2018 Sep;20(5):686-702.
60. Clarke LE, Pimentel JD, et al. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma. *Hum Pathol.* 2017 Dec; 70:113-120.
61. Cockerell C, Ceilley R, et al. Using Genomics to Improve Pigmented Lesion Management & Health Outcomes. *SKIN The Journal of Cutaneous Medicine*, 6(2), 87–89. 2022; <https://doi.org/10.25251/skin.6.2.1>.
62. Cockerell CJ, Tschen J, et al. The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. *Medicine (Baltimore).* 2016 Oct;95(40): e4887.
63. Cockerell C, Tschen J, et al. The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions. *Per Med.* 2017 Mar;14(2):123-130.
64. Committee on Gynecologic Practice, Society of Gynecologic Oncology. Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. *Obstet Gynecol.* 2017 Sep;130(3): e146-e149.
65. Curtis JR, van der Helm-van Mil AH, Knevel R et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. *Arthritis Care Res (Hoboken)* 2012; 64(12): 1794-1803.
66. Cusi K, Budd J, et al. Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know. *Diabetes Spectr.* 2024 Winter;37(1):29-38.
67. Cusi K, Isaacs S, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract.* 2022 May;28(5):528-562.
68. DermTech Inc. Evidence Dossier the DermTech Pigmented Lesion Assay (PLA), 2024.
69. DermTech Inc. Pigmented Lesion Assay (PLA) Clinical Supporting Document, April 2022.
70. Dhillon S, Duarte-Bateman D, et al. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. *Arch Dermatol Res.* 2023 Oct;315(8):2295-2302.
71. Diggans J, Kim SY, Hu Z, et al. Machine learning from concept to clinic: reliable detection of braf v600e DNA mutations in thyroid nodules using high-dimensional RNA expression data. *Pac Symp Biocomput.* 2015; 20:371-382.
72. Doroshow JH, Selecting Systemic Cancer Therapy One Patient at a Time: Is There a Role for Molecular Profiling of Individual Patients with Advanced Solid Tumors? *Journal of Clinical Oncology*, Vol 28, 2010.
73. Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma: Guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clin Proc.* Apr 2017;92(4):578-598.
74. Duchnowska R, et al, Correlation Between Quantitative HER2 Protein Level and the Risk of Brain Metastasis in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Containing Therapy, *J Clin Oncol*, 28:15s, 2010 (suppl; abstr 1030).

75. Dunton Cj, Bullock RG, Fritsche H. Ethnic disparity in clinical performance between multivariate index assay and CA125 in detection of ovarian malignancy. *Future Oncol.* 2019 Sep;15(26):3047-3051.
76. Dunton CJ, Eskander RN, et al. Low-risk multivariate index assay scores, physician referral and surgical choices in women with adnexal masses. *Curr Med Res Opin.* 2020 Dec;36(12):2079-2083.
77. Dunton CJ, Hutchcraft ML, et al. Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative. *Diagnostics* 2021, 11, 1440.
78. ECRI Genetic Test Assessment: DecisionDx-Melanoma (Castle Biosciences, Inc.) for Evaluating Prognosis and Guiding Management of Cutaneous Melanoma; Oct. 2023.
79. ECRI Genetic Test Assessment: Pigmented Lesion Assay (DermTech) for Aiding Melanoma Diagnosis; March 2023.
80. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P et al. Lipid-related markers and cardiovascular disease prediction. *JAMA* 2012; 307(23):2499-506.
81. Eskander RN, Carpenter BA, et al. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients. *Curr Med Res Opin.* 2016 Jun;32(6):1161-5.
82. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). *JAMA* 2001; 285:2486-2497.
83. Fakh M, Sandhu J, et al. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients with Resected Colorectal Cancer. *JAMA Netw Open.* 2022 Mar 1;5(3): e221093. PMID: 35258578.
84. Farberg AS, Marson JW, et al. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group. *Dermatol Ther (Heidelb).* 2022 Apr;12(4):807-823.
85. Ferraro S, Robbiano C, et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up. *Clin Biochem.* 2018 Sep; 60:84-90. Doi: 10.1016/j.clinbiochem.2018.08.003. Epub 2018 Aug 18. PMID: 30125544.
86. First Coast Service Options, Inc. (FCSO). Billing and Coding Article: Billing and Coding: Molecular Pathology and Genetic Testing (A58918); accessed at [fcsso.com](http://fcsso.com).
87. First Coast Service Options, Inc. (FCSO). Billing and Coding Article: Billing and Coding: Molecular Pathology Procedures (A57451); accessed at [fcsso.com](http://fcsso.com).
88. First Coast Service Options, Inc. (FCSO). Local Coverage Determination (LCD) Molecular Pathology Procedures (L34519); accessed at [fcsso.com](http://fcsso.com).
89. First Coast Service Options, Inc. (FCSO). Local Coverage Determination (LCD) Pharmacogenomics Testing (L39073); accessed at [fcsso.com](http://fcsso.com).
90. Foulks GN, Forstot SL, et al. Clinical guidelines for management of dry eye associated with Sjogren disease. *Ocul Surf.* 2015;13(2):118-132.
91. Freudenberg JA, Bembas K, Greene MI, Zhang H, Non-Invasive, Ultra-Sensitive, High-Throughput Assays to Quantify Rare Biomarkers in the Blood, *Methods*, 2008 Jun 20.



92. Fried L, Tan A, et al. Technological advances for the detection of melanoma: Advances in molecular techniques. *J Am Acad Dermatol*. 2020 Oct;83(4):996-1004. PMID: 32360759.
93. Fung MA, Vidal CI, et al. Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee. *J Cutan Pathol*. 2022 Mar;49(3):231-245.
94. Genomic Health, Inc. OncoExTra™ Assay Dossier; 03/23.
95. Goodrich ST, Bristow RE, et al. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. *Am J Obstet Gynecol*. 2014 Jul;211(1):65. e1-65.e11.
96. Gregorc et al, Predictive Value of a Proteomic Signature in Patients with Non-Small-Cell Lung Cancer Treated with Second Line Erlotinib or Chemotherapy (PROSE): A Biomarker-Stratified, Randomised Phase 3 Trial, *The Lancet Oncology*, 2014.
97. Greenhaw BN, Covington KR, et al. Molecular Risk Prediction in Cutaneous Melanoma: A Meta-Analysis of the 31-gene Expression Profile Prognostic Test in 1,479 Patients. *J Am Acad Dermatol*. 2020 Mar 27; S0190-9622(20)30475-8.
98. Greenhaw BN, Zitelli JA, Brodland DG. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test. *Dermatol Surg*. Dec 2018;44(12): 1494-1500. PMID 29994951.
99. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010; 56(25):e50-103.
100. Grossman D, Okwundu N, et al. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. *JAMA Dermatol*. 2020 Sep 1;156(9):1004-1011. PMID: 32725204.
101. Guardant Health Dossier: Use of the Guardant360® Cell-free Circulating Tumor DNA Test in Advanced Non-Small Cell Lung Cancer, 09/12/17.
102. Gunning A, Kumar S, et al. Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers. *Diagnostics (Basel)*. 2023 Feb 14;13(4):725. PMID: 36832208.
103. Gyawali B, West HJ. Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer- Either, Both, or Neither? *JAMA Oncol*. 2019 Feb 1;5(2):148-149. doi:10.1001/jamaoncol.2018.4304
104. Hambardzumayan K et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. *Annals of Rheum Dis* doi:10.1136/annrheumdis-2013-204986.
105. Harrell RM, Bimston DN, Surgical utility of Afirma: effects of high cancer prevalence and oncocyctic cell types in patients with indeterminate thyroid cytology; *Endocr Pract*. 2014 Apr;20(4):364-9.
106. Haugen BR, Alexander EK, Bible KC, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. Jan 2016;26(1):1-133.
107. Havrilesky L, Whitehead C, Rubatt J, et al, Evaluation of Biomarker Panels for Early Stage Ovarian Cancer Detection and Monitoring for Disease Recurrence, *Gynecol Oncol*, 2008 Jun 25.

108. Henriksen TV, Tarazona N, et al. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. *Clin Cancer Res.* 2022 Feb 1;28(3):507-517.
109. Hirata S et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. *Rheumatology (Oxford)* 2013; 52:1202-07.
110. Hornberger et al, Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial, *Lung Cancer*, 2015.
111. Hsueh EC, DeBloom JR, et al. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. *JCO Precis Oncol.* 2021 Apr 6;5:PO.20.00119.
112. Hyams DM, Covington KR, et al. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations. *Future Oncol.* Feb 2021; 17(5):517-527. PMID 33021104.
113. James NE, Chhester C, Ribeiro JR. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer. *Front Oncol.* 2018 Apr 24; 8:124.
114. Janas L. Current clinical application of serum biomarkers to detect and monitor ovarian cancer – update. *Prz Menopauzalny.* 2021 Dec;20(4):211-216.
115. Jamshidi A, Liu MC, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. *Cancer Cell.* 2022 Dec 12;40(12):1537-1549.e12. doi: 10.1016/j.ccell.2022.10.022. PMID: 36400018.
116. Kangas-Dick AW, Greenbaum A, et al. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma. *Ann Surg Oncol.* 2021 Jan 23. PMID:33486642.
117. Kashani-Sabet M, Leachman SA, et al. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. *JAMA Dermatol.* 2023 Mar 15. Doi: 10.1001/jamadermatol.2023.0127. PMID: 36920356.
118. Kasi PM, Chakrabarti S, et al. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. *BMJ Open.* 2022 May 30;12(5): e060342. PMID:35636789.
119. Kjaergaard M, Lindvig KP, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. *J Hepatol.* 2023 Aug;79(2):277-28. PMID: 37088311.
120. Ko JS, Clarke LE, et al. Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions. *Hum Pathol.* 2019 Apr; 86:213-221.
121. Ko JS, Matharoo-Ball B, et al. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. *Cancer EpidemiolBiomarkers Prev.* 2017 Jul;26(7):1107-1113.
122. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol.* 2010 Mar;105(3):501-23; accessed at [gi.org/clinical-guidelines](http://gi.org/clinical-guidelines).

123. Krishna G, Thangaraju Sivakumar P, et al. Potential Utility of Plasma Biomarker Panels in Differential Diagnosis of Alzheimer's Disease. *J Alzheimers Dis Rep.* 2024 Jan 9;8(1):1-7. PMID: 38229828.
124. Lam D, Nadkarni GN, et al. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. *Am J Nephrol.* 2022;53(1):21-31.
125. Lastra RR, Pramick MR, Crammer CJ, et al. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience. *Cancer Cytopathol.* Oct 2014;122(10):737-744.
126. Lawton FB, Pavlik EJ. Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. *Diagnostics (Basel).* 2022 Mar 24;12(4):791.
127. Li AJ, Adnexal mass: Role of serum biomarkers in diagnosing epithelial carcinoma of the ovary, fallopian tube, or peritoneum, 2024. In: *UpToDate*, Goff B, Chakrabarti A (Eds); *UpToDate*, Waltham, MA; accessed at [uptodate.com](https://www.uptodate.com).
128. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: management of Crohn's disease in adults. *Am J Gastroenterol.* Apr 2018;113(4):481-517.
129. Litchman GH, Prado G, et al. A Systematic Review and Meta-Analysis of Gene Expression Profiling for Primary Cutaneous Melanoma Prognosis. *SKIN J Cutaneous Med* 2020; 4:221-37.
130. Liu V, Armstrong AW. Pathologic characteristics of melanoma. In: *UpToDate*, Atkins MB, Tsao H, corona R (Eds), *UpToDate*, Waltham, MA; accessed May 2023 at [uptodate.com](https://www.uptodate.com).
131. Longoria TC, Ueland FR, et al. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. *Am J Obstet Gynecol.* 2014 Jan;210(1):78. e1-9.
132. Loupakis F, Sharma S, et al. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients with Colorectal Cancer Undergoing Resection of Metastases. *JCO Precis Oncol.* 2021 Jul 21;5:PO.21.00101. PMID:34327297.
133. Lowrance WT, Scardino PT, Predictive Models for Newly Diagnosed Prostate Cancer Patients, *Rev Urol.* 2009 Summer; 11(3): 117-126.
134. Magbanua MJM, Swigart LB, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. *Ann Oncol.* 2021 Feb;32(2):229-239. PMID: 33232761. Marchetti MA, Coit DG, et al. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis. *JAMA Dermatol.* 2020 Sep 1;156(9):953-962. PMID:32745161.
135. Matsusaka S, Mizunuma N, Terui Y, et al, Use of Circulating Tumor Cells and Circulating Endothelial Cells as Surrogate Markers for FOLFOX4 With or Without Bevacizumab in mCRC, American Society of Clinical Oncology, 2009 Gastrointestinal Cancers Symposium.
136. McIver B, Castro MR, Morris JC, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. *J Clin Endocrinol Metab.* Nov 2014;99(11):4069-4077.
137. Mack PC, Banks KC, et al. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. *Cancer.* 2020 Jul 15;126(14):3219-3228.

138. Medeiros F, Kolbert CP, Rohakhtar R, et al, A Gene Expression Microarray-Based Diagnostic Test Applied to Patients with Carcinoma of Unknown Primary, *J Clin Oncol* 26: 2008, May 20 suppl.
139. Miller RW, et al, Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines with a Multivariate Index Assay, *Obstetrics & Gynecology*, Vol. 117, NO. 6, June 2011.
140. Minasian LM, Pinsky P, et al. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. *J Natl Cancer Inst.* 2023 Mar 9;115(3):250-257. PMID:36458902.
141. Monzon FA, Henner WD, Medeiros F, Use of a Microarray-Based 1550-Gene Expression Profile in the Diagnosis of Carcinoma of Unknown Primary (CUP), *American Society of Clinical Oncology, 2009 Gastrointestinal Cancers Symposium.*
142. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al, Multicenter Validation of a 1,550 Gene Expression Profile for Identification of Tumor Tissue of Origin, *J Clin Oncol*, Vol 27, No 15, May 2009.
143. Moore RG, Brown AK, Miller CM, Badgwell, et al, Utility of a Novel Serum Tumor Biomarker HE4 in Patients with Uterine Cancer, *Journal of Clinical Oncology*, 2008 May 19.
144. Nadkarni GN, Takale D, et al. A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease. *Kidney360.* 2022 May 18;3(9):1599-1602.
145. Natera™ Signatera™ Residual Disease Test (MRD) Dossier, 03/22.
146. National Comprehensive Cancer Network (NCCN), *Clinical Practice Guidelines in Oncology*; located at [nccn.org](http://nccn.org).
147. National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. 2013; accessed at [nice.org.uk/guidance](http://nice.org.uk/guidance) 12/17/18.
148. Naveris™ NavDx Clinical Dossier, August 2023.
149. Newman JG, Hall MA, et al. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review. *Head Neck.* 2021 Sep; 43(9): 2822–2843.
150. Ordas I, Mould DR, Feagan BG et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. *Clin Pharmacol Ther* 2012; 91(4):635-46.
151. Owens L, Gulati R, Etzioni R. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. *Cancer Epidemiol Biomarkers Prev.* 2022 Jul 1;31(7):1298-1304.
152. Pal SK, Agarwal N, Boorjian SA, et al. National Comprehensive Cancer Network recommendations on molecular profiling of advanced bladder cancer. *J Clin Oncol.* Sep 20, 2016;34(27):3346-3348.
153. Palmetto GBA, MolDX LCDs located at [palmettogba.com](http://palmettogba.com).
154. Piotrowska Z, Drapkin B, et al, Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer. *J Thorac Oncol.* 2016 Aug;11(8): e95-7. Doi: 10.1016/j.jtho.2016.03.020.
155. Pons-Belda OD, Fernandez-Uriarte A, Diamandis EP. Multi Cancer Early Detection by Using Circulating Tumor DNA-The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on “Pons-Belda et al. Can Circulating Tumor DNA Support a Successful

- Screening Test for Early Cancer Detection? The Grail Paradigm. *Diagnostics* 2021, 11, 2171". *Diagnostics* (Basel). 2022 May 17;12(5):1244. doi: 10.3390/diagnostics12051244.
156. Powles T, Assaf ZJ, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. *Nature*. 2021 Jul;595(7867):432-437. PMID:34135506.
  157. Qu KZ, Li H, Whitmire R, Sferruzza A, Bender RA, Human Epididymis Secretory Protein 4 in Serum (HE4) as a Marker of Ovarian Cancer, *J Clin Oncol* 26: 2008, May 20 suppl.
  158. Raghav K, Morris V, et al, MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. *Oncotarget*. 2016 Jul 13. Doi: 10.18632/oncotarget.10559.
  159. Rauniyar N, Peng G, et al, Data-Independent Acquisition and Parallel Reaction Monitoring Mass Spectrometry Identification of Serum Biomarkers for Ovarian Cancer; *Biomark Insights*. 2017 Jun 5; 12:1177271917710948.
  160. Reilly GP, Dunton CJ, et al. Validation of a deep neural network-based algorithm supporting clinical management of adnexal mass. *Front Med (Lausanne)*. 2023 Jan 23; 10:1102437.
  161. Reilly GP, Gregory DA, et al. A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk. *J Comp Eff Res*. 2023 Jun; 12(6): e230025. Published online 2023 May 22.
  162. Rinella ME, Neuschwander-Tetri BA, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023 May 1;77(5):1797-1835.
  163. Ross JS, et al, The Her-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine, *The Oncologist* 2009; 14: 320-368.
  164. Santos ES, Raez LE, et al; Genomic Tissue Analysis and Liquid Biopsy Profiles from Patients Diagnosed with Advanced Adenocarcinoma of the Lung. *Clin Oncol*. 2016; 1: 1099.
  165. Sax JL, McFarland CD, Carrol BT. Limitations of the Commercially Available Gene Expression Test in Predicting Cutaneous Squamous Cell Carcinoma Metastasis and Clinical Outcomes. *J Am Acad Dermatol*. 2024 May 16: S0190-9622(24)00746-1. PMID: 38762012.
  166. Schraen-Maschke S, Duhamel T, et al. The free plasma amyloid A $\beta$  1 – 42 /A $\beta$  1 – 40 ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma A $\beta$  1 – 42 /A $\beta$  1 – 40 ratio. The BALTAZAR study. *Neurobiol Dis*.2024 Apr:193:106459. PMID: 38423192.
  167. Schrock AB, Welsh A, et al. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2019 Feb;14(2):255-264. Doi: 10.1016/j.jtho.2018.10.008. Epub 2018 Oct 24. PMID: 30368012.
  168. Schwaederle M, Husain H, et al, Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. *Oncotarget*. 2016 Mar 1;7(9):9707-17. Doi: 10.18632/oncotarget.7110.
  169. Sharma C, Cococcia S, et al. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. *J Gastroenterol Hepatol*. 2021 Jul;36(7):1788-1802. PMID: 33668077.
  170. Sheth S, Walburn T, et al. Plasma Circulating HPV DNA Surveillance in a Patient With Nasopharyngeal Cancer. *Ear Nose Throat J*. 2024 Sep 12:1455613241278756. PMID: 39264198.

171. Siemens Healthineers. Enhanced Liver Fibrosis (ELF™) Product Overview; August 2023.
172. Singer J, Hanna JW, et al, Impact of a gene expression classifier on the long-term management of patients with cytologically indeterminate thyroid nodules. *Curr Med Res Opin*. 2016 Jul;32(7):1225-32.
173. Skelsey M, Brouha B, et al. Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden. 2021 SKIN The Journal of Cutaneous Medicine, 5(5), 512–523.
174. Skudalski L, Waldman R, et al. Melanoma: How and when to consider clinical diagnostic technologies. *J Am Acad Dermatol*. 2022 Mar;86(3):503-512. PMID: 34915058.
175. Society of Gynecologic Oncologists, Statement Regarding OVA1, 09/09, accessed at [sgo.org](http://sgo.org).
176. Society of Gynecologic Oncologists, Statement Regarding OvaCheck™, 07/08, accessed at [sgo.org](http://sgo.org).
177. Society of Gynecologic Oncologists, Statement Regarding OvaSure™, 07/08, accessed at [sgo.org](http://sgo.org).
178. Spitzer G, Socinski MA. Alternative Strategy to Achieve Increased Overall Survival and Better Quality of Life in Patients with Second-Line Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2015;33(5):522-523.
179. Steward DL, Kloos RT, Clinical Diagnostic Gene Expression Thyroid Testing; *Otolaryngol Clin North Am*. 2014 Aug;47(4):573-93.
180. Stinchcombe et al, Clinical Validity Data: Phase II Blinded Study, *Journal of Thoracic Oncology*, 2013.
181. Swetter S, Geller AC. Melanoma: Clinical features and diagnosis. In: UpToDate, Tsao H, Corona R (Eds), UpToDate, Waltham, MA; accessed at [uptodate.com](http://uptodate.com).
182. Swetter SM, Tsao H, et al. Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol*. 2019 Jan;80(1):208-250; accessed at [jaad.org](http://jaad.org).
183. Sullivan PS, Hirschowitz SL, et al, The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System; *Cancer Cytopathol*. 2014 Dec;122(12):866-72.
184. Taguchi et al, Development and Initial Validation of VeriStrat, *Journal of the National Cancer Institute*, 2007.
185. Tanaka F, Hashimoto M, Takuwa T, et al, Circulating Tumor Cells (CTCs) and endothelial Cells (CECs) in Malignant Pleural Mesothelioma (MPM) and Primary Lung Cancer, *J Clin Oncol* 26: 2008 May 20 suppl.
186. Tang WHW, Yimer H, et al. Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity. *Prev Med*. 2023 Feb; 167:107384. PMID: 36495927.
187. Thompson JC, Yee SS, et al; Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. *Clin Cancer Res*. 2016 Sep 6.
188. Tie J, Cohen JD, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *N Engl J Med*. 2022 Jun 16;386(24):2261-2272.

189. Tokita J, Vega A, et al. Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes. *J Prim Care Community Health*. 2022 Jan-Dec; 13:21501319221138196.
190. Tran MC, Strohbehn GW, et al. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. *Clin Lung Cancer*. 2023 May;24(3): e117-e121.
191. Tschen J, Davies P, et al. Clinical Use of a Diagnostic Gene Expression Signature for Melanocytic Neoplasms. *Cutis*. 2021 May;107(5):264-269.
192. Ueland FR. Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum. In: *UpToDate*, Goff B, Chakrabarti A (Eds), *UpToDate*, Waltham, MA; accessed at [uptodate.com](https://www.uptodate.com).
193. Ueland FR, A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come; *Diagnostics (Basel)*. 2017 Mar; 7(1): 14.
194. Ueland FR, Desimone CP, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. *Obstet Gynecol*. 2011 Jun;117(6):1289-97.
195. U.S. Food and Drug Administration (FDA); accessed at [fda.gov](https://www.fda.gov).
196. U.S. Food and Drug Administration (FDA). List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools); accessed at [fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools](https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools).
197. U.S Preventive Services Task Force (USPSTF), USPSTF Recommendations, accessed at: [uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org).
198. Urban RR, Smith A, et al. Evaluation of a Validated Biomarker Test in Combination with a Symptom Index to Predict Ovarian Malignancy. *Int J Gynecol Cancer*. 2017 Feb;27(2):233-238.
199. Vermillion Inc. Dossier: The Clinical and Economic Value of OVA1/MIA, 04/20/17.
200. Vermillion Inc. Presentation: OVA1<sup>®</sup> Testing and Optimal Management of the Adnexal Mass. April 2019.
201. Vetto JT, Hsueh EC, et al. Guidance of Sentinel Lymph Node Biopsy Decisions in Patients with T1-T2 Melanoma Using Gene Expression Profiling. *Future Oncol*. 2019 Apr;15(11):1207-1217.
202. Viera AJ. Overview of preventive care in adults – *UpToDate*. Elmore JG, Givens J, Swenson S (Eds.); accessed June 2023 at [uptodate.com](https://www.uptodate.com).
203. Villaflor V, Won B, et al, Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. *Oncotarget*. 2016 Sep 1. Doi: 10.18632/oncotarget.11801.
204. Visintin I, Feng Z, Longton G, Ward D, et al, Diagnostic Markers for Early Detection of Ovarian Cancer, *Clinical Cancer Research* 14, 1065-1072, February 15, 2008.
205. Wang SL, Hauenstein S, et al, Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay, *Journal of Pharmaceutical and Biomedical Analysis* 78– 79 (2013) 39– 44.
206. Wattacheril JJ, Abdelmalek MF, et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology*. 2023 Oct;165(4):1080-1088.

207. White T, Szelinger S, et al. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra<sup>®</sup>, Oncotarget. 2021 Apr 13;12(8):726-739. Doi: 10.18632/oncotarget.27945.
208. Wu J, Yan F, Zhang X, et al, Disposable Reagentless Electrochemical Immunosensor Array Based on a Biopolymer/Sol-Gel Membrane for Simultaneous Measurement of Several Tumor Markers, Clinical Chemistry, June 2008.
209. Younossi ZM, Felix S, et al. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2021 Sep 1;4(9):e2123923.
210. Zager JS, Gastman BR, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. Feb 05, 2018; 18(1): 130. PMID 29402264.
211. Zhang S, Brazel D, et al. Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies. J Gastrointest Oncol. 2021 Dec;12(6):2643-2652. PMID:35070394.
212. Zhou C, Yuan X, et al. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. J Hematol Oncol. 2018 Nov 6;11(1):129.
213. Ziyambe B, Yahya A, et al. A Deep Learning Framework for the Prediction and Diagnosis of Ovarian Cancer in Pre- and Post-Menopausal Women. Diagnostics (Basel). 2023 May 11;13(10):1703.
214. Zubek VB, Konski A, Cost Effectiveness of Risk-Prediction Tools in Selecting Patients for Immediate Post-Prostatectomy Treatment, Molecular Diagnosis & Therapy, Volume 13, Number 1, 2009, pp. 31-47.

### COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 12/05/24.

### GUIDELINE UPDATE INFORMATION:

02/15/04	Developed separate guideline for non-covered tumor markers from the Tumor Markers guideline. Added program exception and added diagnoses [155.1, 156.1, 156.8, 156.9, 157.0 – 157.9, 197.8, 235.3, 235.5, V10.09] for 86301 for Medicare & More.
02/15/05	Deleted CA 19-9 from the investigational statement. Deleted Medicare program exception. Deleted the following from the when services are covered section of the MCG (per MPCC recommendation): Non-covered/investigational serum tumor markers may be covered if the individual subscriber has a benefit to cover non-covered/investigational services (refer to contract benefits). Updated related guidelines section.
08/15/07	Review, investigational status maintained, guideline reformatted, references updated.
09/15/08	Annual review: Position statements maintained. Description section and references updated.



08/15/09	Annual review: Guideline title changed, position statements updated, position statements from other tumor marker guidelines incorporated, description section, coding and references updated.
12/15/09	Updated the list of experimental/investigational tests.
01/01/10	Annual HCPCS coding update: added code 86305.
04/15/10	Updated the list of experimental/investigational tests and the Medicare Advantage program exception.
11/15/10	Revision; updated the list of experimental/investigational tests and added related ICD-10 codes.
08/15/11	Revision; Medicare Advantage and references updated; formatting changes.
01/01/12	Annual HCPCS update. Added CPT codes 0279T, 0280T.
04/01/12	Quarterly HCPCS update. Deleted HCPCS code S3711.
08/24/12	Reimbursement section updated.
10/15/12	Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease position statement removed and added to the Genetic Testing guideline; reimbursement section updated.
11/15/12	List of experimental/investigational tests updated.
01/01/13	Annual HCPCS update. Added codes 81500, 81503, 81506, 86152, 86153, 0001M-0003M; deleted codes 0279T & 0280T. Updated position statement section and references.
02/15/13	Revision; position statement section and references updated.
03/15/13	Revision; position statement section including the list of investigational tests and references updated; title change.
05/15/13	Revision; position statement, billing/coding, program exception, and reference sections updated.
09/15/13	Revision; position statement section and references updated.
01/01/14	Annual HCPCS update. Added code 81504.
02/15/14	Revision; position statement section, Medicare program exception, and references updated.
06/15/14	Revision; position statement section, Coding, Medicare program exception, and references updated.
07/01/14	Quarterly HCPCS update. Added code 0007M.
10/15/14	Revision; Update the position statement and coding sections, program exception, and references.
01/01/15	Annual HCPCS/CPT update. Added codes 87505-87507.
06/15/15	Revision; position statement section, billing/coding, and references updated.
11/01/15	Revision: ICD-9 Codes deleted.
11/15/15	Revision; program exception and references updated.
01/01/16	Annual HCPCS/CPT update; codes 81490, 81538, 81540, 81545 added, code 0103T deleted.
03/15/16	Revision; position statement section, coding and references updated.
09/15/16	Revision; position statement section, program exception, and references updated.
11/15/16	Revision; position statement section and references updated.
12/15/16	Revision; position statement, coding, and references updated.
02/01/17	Coding Update; new code 0003U added; investigational test list updated.

02/15/17	Revision; position statements, coding, and references updated.
03/15/17	Revision; Multianalyte assays for chronic liver disease position statements revised; coding and references updated.
04/15/17	Revision; Uveal Melanoma position statement added and references updated.
06/15/17	Revision; test names added to Biochemical Markers of Alzheimer's Disease & Circulating Tumor DNA position statements section; investigational test list updated.
07/15/17	Revision; Investigational test list updated.
08/01/17	Coding update; Added code 0009U.
12/15/17	Revision; Position statement section updated including the addition of ROS1 coverage statement; program exception and references updated.
01/01/18	Annual CPT/HCPCS update. Added code 0026U.
02/15/18	Revision; Circulating tumor DNA position statement added; OVA1, Overa, and ROMA tests position statement added and references updated.
04/01/18	Quarterly HCPCS/CPT update. Added codes 0012M and 0013M.
05/15/18	Revision; position statements, coding, and references updated.
09/15/18	Revision; position statements and references updated.
10/01/18	Quarterly HCPCS/CPT update. Added code 0062U.
12/15/18	Revision; Guardant360 test and OncoBEAM test added to the circulating tumor DNA for management of NSCLC position statement; investigational statement for microarray-based gene expression profile testing for multiple myeloma added; molecular analysis for targeted therapy of NSCLC position statements updated; coding, and references updated.
01/01/19	Annual CPT/HCPCS coding update. Added codes 81345, 81596; deleted code 0001M.
02/15/18	Revision; Fecal calprotectin testing position revised; coding and references updated.
05/15/19	Revision; Serum Biomarker Human Epididymis Protein 4 position statement added; references updated.
06/15/19	Revision; Xpresys test deleted (test no longer on the market).
07/01/19	Quarterly CPT/HCPCS update; Added codes 0089U-0092U. Revision; Gene expression profiling for cutaneous melanoma & molecular testing in the management of pulmonary nodules position statements added; OVA1 status maintained; coding and references updated.
08/15/19	Revision; Afirma test name updated.
01/01/20	Review; Analysis for targeted therapy of NSCLC & circulating tumor DNA for management of NSCLC statements updated; coding and references updated. Annual CPT/HCPCS coding update. Added codes 80145, 80230, 80280, 81552; deleted code 0081U.
04/01/20	Quarterly CPT/HCPCS update. Added code 0166U.
05/15/20	Coding and references updated.
07/01/20	Gene expression profiling for cutaneous melanoma reviewed and position statements maintained; references updated. Quarterly CPT/HCPCS update. Added codes 0174U & 0179U.
09/15/20	Revision; References updated.
09/18/20	Revision; Liquid biopsy test names updated.
10/01/20	Quarterly CPT/HCPCS update. Added codes 0016M, 0204U-0208U, and 0211U.
11/15/20	Revision; coding and references updated.

01/01/21	Annual CPT/HCPCS update. Codes 81191-81194,81529,81546,81554 added; codes 81545, 0111T deleted.
02/15/21	Review; Circulating tumor DNA management of NSCLC, molecular analysis for targeted therapy for NSCLC, measurement of serum antibodies to selected biologic agents, and pharmacogenomics markers for members treated with thiopurines position statements updated; coding and references updated.
04/01/21	Quarterly CPT/HCPCS update. Codes 0242U, 0244U, 0245U added.
04/16/21	Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) statement added.
05/15/21	Revision; Homocysteine position statement deleted; investigational test list, coding and references updated.
06/15/21	Reimbursement section updated.
07/01/21	Quarterly CPT/HCPCS update. Codes 0249U and 0250U added.
08/15/21	Review; DecisionDx-Melanoma position statement maintained, references updated.
09/03/21	Revision: Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) section updated.
10/15/21	Review; OVA1 position statement maintained, references updated.
11/15/21	Revision; Fecal Calprotectin position statement removed; coding and references updated.
01/01/22	Annual CPT/HCPCS coding update. Codes 0287U, 0288U added; 0090U revised; 0208U deleted.
02/15/22	Revision: Liquid biopsy for management of NSCLC position statements moved to the molecular analysis for targeted therapy or immunotherapy of NSCLC section; statements for KRAS testing for treatment with sotorasib added; coding and references updated.
04/01/22	Quarterly CPT/HCPCS update. Code 0314U added.
04/29/22	Codes 81445-81455 removed.
06/15/22	Expanded test panel list updated.
07/01/22	Review: Gene expression profiling for cutaneous melanoma position statements maintained; references updated. Quarterly CPT/HCPCS update: code 0016M revised.
08/15/22	Review: OVA1 position statement maintained; references updated.
09/15/22	Review: Comprehensive genomic profiling statement removed; investigational test list, coding section, and references updated.
10/01/22	Revision: Tumor-informed circulating tumor DNA testing for cancer management investigational statement added; references updated. Quarterly CPT/HCPCS update. Codes 0337U, 0338U, 0340U added; codes 0013U, 0014U, 0056U deleted.
11/15/22	Revision: Gene expression profiling for colorectal cancer statement added; coding and references updated.
01/01/23	Annual CPT/HCPCS coding update. Codes 84433 and 0363U added.
06/15/23	Revision: Note added to the position statement section. References and coding updated.
07/15/23	Revision: Gene expression profiling for cutaneous melanoma position statements maintained; investigational test list, coding, and references updated.
08/15/23	Revision: Multicancer early detection testing investigational position statement added; references updated.

10/01/23	Revision: Position statements, coding, and references updated. Quarterly CPT/HCPCS coding update: Code 0412U added.
11/15/23	Revision: Multimarker serum testing related to ovarian cancer statement updated; investigational test list, coding, and references updated.
01/01/24	Position statements maintained. Annual CPT/HCPCS coding update. Codes 81517, 0420U added. Program exception and references updated.
03/15/24	Coding and references updated.
04/01/24	Quarterly CPT/HCPCS coding update: Code 0445U added.
04/15/24	Investigational test list, coding, and references updated.
07/01/24	Quarterly CPT/HCPCS coding update. Code 0204U deleted.
08/15/24	Review: Position statements and investigational test list reviewed and updated; description, coding and references updated.
10/01/24	Quarterly CPT/HCPCS coding update. Codes 0490U-0492U added.
12/15/24	Revision: Alzheimer disease CSF biomarker testing statement updated; multianalyte assays for chronic liver disease statements maintained; investigational test list, coding, and references updated.